ANIK: Anika Therapeutics, Inc. - Summary | Jitta

Anika Therapeutics, Inc.

NASDAQ:ANIK

Price
$23.41
Loss Chance
50.3%
3.77JITTA SCORE
254.02%Over Jitta Line
Jitta Ranking
121 / 603
387 / 1,198
3,075 / 5,124
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (33)
Recent Business Performance (29)
Financial Strength (87)
Return to Shareholders (18)
Competitive Advantage (39)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
SG&A to SalesIncreasing Every Year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.77
254.02%
1.34
135.68%
2.05
145.52%
Biotechnology
6.31
61.77%
4.14
65.17%
5.09
7.58%
COMPANY DESCRIPTION
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company’s non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.